{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05488548",
            "orgStudyIdInfo": {
                "id": "EP31670-01"
            },
            "organization": {
                "fullName": "Epigenetix, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors",
            "officialTitle": "A Phase 1 Study of EP31670, a Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "dual-bet-and-cbp-inhibitor-in-patients-with-targeted-advanced-solid-tumors"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-02",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-12-21",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-06",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-09",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-07-27",
            "studyFirstSubmitQcDate": "2022-08-03",
            "studyFirstPostDateStruct": {
                "date": "2022-08-04",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-02-15",
            "lastUpdatePostDateStruct": {
                "date": "2023-02-16",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Epigenetix, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "A Phase 1, first-in-human study of EP31670, a dual BET and CBP/p300 inhibitor in patients with targeted advanced solid tumors.",
            "detailedDescription": "EP31670 (also known as NEO2734) is a first-in-class dual BET and CBP/p300 inhibitor which has demonstrated antitumor activity in in vitro and in vivo models of human cancer. This Phase I open-label, multi-center, dose-escalation study will assess the safety and determine the maximum tolerated dose of EP31670 administered orally in patients with castration-resistant prostate cancer, NUT midline carcinoma and other targeted advanced solid tumors."
        },
        "conditionsModule": {
            "conditions": [
                "Castrate Resistant Prostate Cancer",
                "NUT Carcinoma"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "interventionModelDescription": "Dose escalation/de-escalation will follow rules by employing the Bayesian optimal interval (BOIN) method.",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 50,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Arm 1",
                    "type": "EXPERIMENTAL",
                    "description": "Patients will be assigned escalated dose according to BOIN design. The starting dose is 5 mg orally once a day for 7 consecutive days followed by 14 days of rest.",
                    "interventionNames": [
                        "Drug: EP31670"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "EP31670",
                    "description": "EP31670 (also known as NEO2734) is a first-in-class dual BET and CBP/p300 inhibitor.",
                    "armGroupLabels": [
                        "Arm 1"
                    ],
                    "otherNames": [
                        "NEO2734"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Maximum Tolerated Dose (MTD)",
                    "description": "MTD is the highest dose level at which \u226430% of patients experienced DLTs during cycle 1.",
                    "timeFrame": "Within 3 weeks (one cycle) of treatment"
                },
                {
                    "measure": "Dose Limiting Toxicities (DLT)",
                    "description": "DLT is any of the following adverse events (AEs) that occur during cycle 1.",
                    "timeFrame": "Within 3 weeks (one cycle) of treatment"
                },
                {
                    "measure": "Recommended Phase 2 Dose (RP2D)",
                    "description": "RP2D will be the MTD",
                    "timeFrame": "through study completion, an average of 1 year"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Relapse or refractory castration-resistant prostate cancer (CRPC) following at least one anti-androgen regimen and a docetaxel-containing regimen OR\n* metastatic or unresectable NUT midline carcinoma for which standard curative or palliative measures do not exist; OR\n* patients who have other types of relapsed or refractory solid tumors with pathological and/or biological features suggesting a potential benefit from dual BET and CBP/p300 inhibition may be enrolled after discussion with and approval from medical monitor and sponsor\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n* Life expectancy \u2265 3 months\n* Evaluable disease\n* Adequate bone marrow function:\n\nHemoglobin \u2265 9.0 g/dL Absolute neutrophil count (ANC) \u2265 1,500/dL Platelet count \u2265100,000/\u03bcL\n\n* Adequate renal function:\n\nCreatinine clearance (CLcr) estimated by Cockcroft-Gault Equation to be \u2265 60 mL/min. Estimated glomeruli filtration rate (eGRF) \u2265 60 mL/min may be used if provided by the testing laboratory\n\n* Adequate liver function\n\n  * Total bilirubin \u2264 1.5 x ULN except in patients diagnosed with Gilbert's disease for which direct bilirubin must be \u2264 1.5 x ULN\n  * Alanine aminotransferase (ALT) or aspartate Aminotransferase (AST) \u2264 2.5 x ULN or \u2264 5 x ULN in patients with liver metastases\n* Internal normalized ratio for prothrombin time (INR) \u2264 1.2 in patients not receiving chronic anticoagulation\n* Four weeks from prior anti-cancer therapy including chemotherapy, immunotherapy, investigational anti-cancer therapy or 5 half-lives from targeted agents, radiation and have recovered from prior treatment toxicities to grade 1 or less. Prostate cancer patients may continue androgen-deprivation therapy by luteinizing hormone-releasing hormone (LHRH) agonists.\n* Four weeks from major surgery.\n* For fertile men and women, agreement to use effective contraceptive methods duration of study participation and 4 weeks after the last dose of study drug.\n* Ability to understand and willingness to sign the informed consent form.\n\nExclusion Criteria:\n\n* New and progressive central nervous system (CNS) metastasis; patients with treated brain metastases are eligible if follow-up brain imaging at least 4 weeks after CNS-directed therapy shows no evidence of progression and the patient is neurologically stable\n* Corrected QT interval \u2265470 msec\n* Uncontrolled concurrent illnesses including, but not limited to, ongoing active infection requiring intravenous antibiotics or antifungal agents, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia or psychiatric illness/social situations that would affect compliance with study requirements; patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of EP31670 are eligible for this trial\n* Pregnant or lactating women\n* Known history of hepatitis B, hepatitis C requiring antiviral treatment\n* Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Judy Chiao, MD",
                    "role": "CONTACT",
                    "phone": "(561) 865-6098",
                    "email": "studies@epigenetix.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Judy Chiao, MD",
                    "affiliation": "Epigenetix, Inc.",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Dana Farber Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02215",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Atish Choudhury, MD",
                            "role": "CONTACT",
                            "phone": "877-442-3324"
                        },
                        {
                            "name": "Jia Luo, MD",
                            "role": "CONTACT",
                            "phone": "877-442-3324"
                        },
                        {
                            "name": "Atish Choudhury, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "The University of Texas MD Anderson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Rabia Khan",
                            "role": "CONTACT",
                            "phone": "713-563-4667",
                            "email": "RKhan@MDAnderson.org"
                        },
                        {
                            "name": "Sarina A Piha-Paul, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "University of Washington/Fred Hutchinson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Seattle",
                    "state": "Washington",
                    "zip": "98109",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Chi Westerhold",
                            "role": "CONTACT",
                            "phone": "206-606-7551",
                            "email": "phase1clinicaltrial@seattlecca.org"
                        },
                        {
                            "name": "Michael Schweizer, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 47.60621,
                        "lon": -122.33207
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "pmid": "36125208",
                    "type": "DERIVED",
                    "citation": "Eickhoff N, Bergman AM, Zwart W. Homing in on a Moving Target: Androgen Receptor Cistromic Plasticity in Prostate Cancer. Endocrinology. 2022 Oct 11;163(11):bqac153. doi: 10.1210/endocr/bqac153."
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000011471",
                    "term": "Prostatic Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000005834",
                    "term": "Genital Neoplasms, Male"
                },
                {
                    "id": "D000014565",
                    "term": "Urogenital Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000005832",
                    "term": "Genital Diseases, Male"
                },
                {
                    "id": "D000091662",
                    "term": "Genital Diseases"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000011469",
                    "term": "Prostatic Diseases"
                },
                {
                    "id": "D000052801",
                    "term": "Male Urogenital Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M14335",
                    "name": "Prostatic Neoplasms",
                    "asFound": "Castrate Resistant Prostate Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M8946",
                    "name": "Genital Neoplasms, Male",
                    "relevance": "LOW"
                },
                {
                    "id": "M17315",
                    "name": "Urogenital Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M2876",
                    "name": "Genital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8944",
                    "name": "Genital Diseases, Male",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14333",
                    "name": "Prostatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27095",
                    "name": "Male Urogenital Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                }
            ]
        }
    },
    "hasResults": false
}